RxDoctor Payments Data

Mark Segal, MD

Nephrology · Gainesville, FLNPI 1477574085

Payments from drug & device makers

$233,339in general payments, 2019–2025

Across 52 payments — averaging $4487.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim International GmbH$89K
  • AstraZeneca$76K
  • Boehringer Ingelheim Pharma GmbH & Co.kg$67K
  • Boehringer Ingelheim$362
  • Takeda Pharmaceuticals U.S.A., Inc.$150
  • Amgen$132
  • plus $15 from 1 others

What the payments were for

  • Speaking & faculty fees$15023%
  • Travel & lodging$35454%
  • Food & beverage$15523%

General payments by program year

22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$233,339 in reported general payments places this provider in the 90th percentile of 756 nephrology providers in Florida.

See all nephrology providers in Florida

Medicare billing

Part B allowed, 2024
$13,440
Medicare patients
50
Services billed
152

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LupkynisVoclosporin11$149,739
BenlystaBelimumab18$84,403
JardianceEmpagliflozin17$13,543
Mycophenolate Mofetil109$12,627
Hydroxychloroquine Sulfate114$4,687
Tacrolimus21$3,927
Azathioprine25$1,441
Chlorthalidone87$1,145
Losartan Potassium73$646
Omeprazole15$644
Lisinopril47$514
Atorvastatin Calcium50$442
Prednisone17$406
Allopurinol46$384
Famotidine23$288

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$362$13,54317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 756 nephrology providers in Florida.

Other nephrology in Gainesville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →